Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study()

BACKGROUND: Clinical studies have demonstrated that IL-17A inhibition with secukinumab is effective for clearing the skin of patients with psoriasis and has a favorable safety profile. OBJECTIVE: The authors aim to determine whether secukinumab is effective and safe for the treatment of moderate-to-...

Descripción completa

Detalles Bibliográficos
Autores principales: Oguz Topal, Ilteris, Baysak, Sevim, Altunay, İlknur Kıvanç, Kara Polat, Asude, Arıkan, Eylem Emel, Özkur, Ezgi, Aytekin, Sema, Dogan, Bilal, Özkök Akbulut, Tuğba, Topaloğlu Demir, Filiz, Karadağ, Ayşe Serap
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453482/
https://www.ncbi.nlm.nih.gov/pubmed/35843765
http://dx.doi.org/10.1016/j.abd.2021.11.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453482/
https://www.ncbi.nlm.nih.gov/pubmed/35843765
http://dx.doi.org/10.1016/j.abd.2021.11.002

Ejemplares similares